H.C. Wainwright Maintains Their Buy Rating on Protagonist Therapeutics (PTGX)

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Protagonist Therapeutics (PTGX) today and set a price target of $33.00. The company’s shares closed last Wednesday at $23.44, close to its 52-week high of $24.96.

According to TipRanks.com, Tsao is a 4-star analyst with an average return of 12.1% and a 52.2% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Minerva Neurosciences, and Revance Therapeutics.

Protagonist Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $39.50, a 61.4% upside from current levels. In a report issued on December 7, BMO Capital also maintained a Buy rating on the stock with a $46.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $24.96 and a one-year low of $5.30. Currently, Protagonist Therapeutics has an average volume of 365.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm’s initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn’s disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts